Obermatt
See Similar Stocks →

Royalty Pharma

NSQ:RPRX · GB00BMVP7Y09
PharmaceuticalsMedium

360

51
Profit price59
Cash yield97
Price/Sales61
EV / Gross Profit17
Price/Book48
Return on Capital25
Return on Equity53
EBIT Margin100
Gross Profitability1
Cash Conversion94
Accruals27
Sales growth44
Profit Growth93
Long-Term EPS Growth52
Reinvestment37
Price momentum57
Debt load12
Debt serviceability96
Liquidity77
Analyst ratings47
Opinion Changes62
Price Target Upside36
Market mood34
Value Creation7/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Royalty Pharma clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2020
Employees77
Websiteroyaltypharma.com
ISINGB00BMVP7Y09
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)D.J. US Health CareD.J. US Pharmaceutical
Themes
NeurologyChronic DiseasesInfectious DiseasesImmunologyHematologyGeneticsCentral Nervous SystemNeuroscienceOncology

Description

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company is a pioneer in the royalty market, collaborating with innovators from academic institutions, researc…

Analysis

Middle-of-the-road

Royalty Pharma plc is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 7/20 on our value-creation score: creating some value. Analysts lean positive.

What to watch: The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
100
2023202420252026

All-time high

100

Jun 2026

All-time low

51

Jan 2023

Average rank

85

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
61
11
14
12
Price/Earnings
22
93
95
75
Price/Book
48
65
60
50
Dividend Yield
97
94
94
92
Value (overall)
82
96
96
83

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Royalty Pharma with its peers
Vertex Pharmaceuticals
NSQ:VRTX
63
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Ligand Pharmaceuticals
NMQ:LGND
64
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Pfizer Limited
NSI:PFIZER
65
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Pfizer
NYQ:PFE
34
CountryUSA
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Johnson & Johnson
NYQ:JNJ
64
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Edgewise Therapeutics
NSQ:EWTX
49
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →